Apellis Pharmaceuticals (NASDAQ:APLS) Coverage Initiated at Piper Sandler
Research analysts at Piper Sandler began coverage on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) in a note issued to investors on Friday, MarketBeat Ratings reports. The brokerage set a “neutral” rating and a $46.00 price target on the stock. Piper Sandler’s target price points to a potential upside of 17.20% from the […]
More Stories
DOJ Sues Connecticut, City of New Haven Over Sanctuary Policies
By Jackson Richman The U.S. Department of Justice (DOJ) sued Connecticut and the City of New Haven on April 13...
Israel–Lebanon Talks Conclude With Signs of Progress But No Ceasefire Deal
By Ryan Morgan U.S. Secretary of State Marco Rubio hosted the Israeli and Lebanese ambassadors to the United States for...
DEI Practices Reduce Productivity, Cost $94 Billion Annually: White House Economic Report
By Travis Gillmore WASHINGTON—Diversity, equity, and inclusion practices negatively impacted the U.S. economy, according to the 2026 White House Economic...
Fauci Deputy Who Declined COVID-19 Vaccine Feared Retaliation: Emails
By Zachary Stieber A top government doctor who declined to receive a COVID-19 vaccine in 2021 was worried he would...
20+ SEO Checklist For Blog Posts: Read Before Publishing
You wrote a fantastic blog. What’s next? Publishing blogs without optimizing them for SEO is like starting a shop without...
US Military Blockade on Iranian Ports Goes Into Effect, Maritime Group Says
By Jack Phillips A scheduled U.S. naval blockade of the Strait of Hormuz and nearby waters started at 10 a.m....